Wird geladen...
CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma–Kinase Inhibition Redux
In the January 15, 2012, issue of Clinical Cancer Research, Kirkwood and colleagues published a study comparing the MEK inhibitor selumetinib to temozolomide in unselected metastatic melanoma. Although selumetinib did not improve survival or response, most responders had BRAF activating mutations, a...
Gespeichert in:
| Veröffentlicht in: | Clin Cancer Res |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2015
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4683414/ https://ncbi.nlm.nih.gov/pubmed/26672083 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-3132 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|